Contraceptive Drugs and Devices Market Size & Growth Forecast 2026–2035, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Contraceptive Drugs and Devices Market size was around USD 32.42 Billion in 2025 and is slated to grow at a 6.1% CAGR from 2026 to 2035, surpassing USD 58.61 Billion by 2035. The industry revenue for 2026 is assessed at USD 34.14 billion.
Get more details on this report
Request Free Sample ReportContraceptive Drugs and Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to broad product availability, established prescribing and retail channels, mature healthcare systems, and routine use of short- and long-acting contraceptive options.
- Asia Pacific grows at 6.89% CAGR driven by rising family planning awareness, improving healthcare access, expanding contraceptive availability, and stronger pharmacy and counseling services across urban and semi-urban regions.
Segment Momentum
- Contraceptive Devices hold a 66.54% share due to long-acting, procedure-based effectiveness and reduced reliance on daily adherence, making them widely preferred in routine contraceptive care settings.
- Growth is driven by increasing preference for reliable, convenient, long-acting methods that reduce user dependency and align with evolving healthcare priorities for consistent and low-maintenance contraception.
Market Expansion Drivers
- Rising global focus on reproductive health awareness and family planning programs driving adoption.
- Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness.
- Expanding government-led contraception access initiatives improving affordability in developing regions.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Top players in the contraceptive drugs and devices market include Bayer AG (Germany), Organon & Co. (United States), Pfizer Inc. (United States), AbbVie Inc. (United States), Viatris Inc. (United States), Johnson & Johnson (United States), Church & Dwight Co., Inc. (United States), Veru Inc. (United States), Cupid Limited (India), Agile Therapeutics, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As public health agencies, NGOs, and healthcare providers place greater emphasis on reproductive health education, the contraceptive drugs and devices market benefits from a broader shift in consumer behavior from reactive pregnancy prevention to planned, informed contraceptive use. Family planning programs improve awareness of available methods, reduce stigma around discussing contraception, and bring first-time users into clinical settings where counseling often leads to method selection based on lifestyle, safety, and duration needs. This raises prescription volumes for hormonal products while also supporting uptake of provider-administered devices, driving market development through higher conversion from awareness to actual product use.
Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness
A growing tilt toward long-acting reversible contraceptives is reshaping the contraceptive drugs and devices market by favoring products that reduce user error and limit the need for frequent refills or daily adherence. In practice, clinicians and patients increasingly prioritize methods such as intrauterine devices and implants because their duration and reliability improve continuation rates compared with short-cycle options. That preference influences procurement patterns, provider training, and product mix, with demand moving toward higher-value device categories that support market expansion through sustained usage and lower discontinuation linked to missed doses or inconsistent compliance.
Expanding government-led contraception access initiatives improving affordability in developing regions
Public-sector contraception programs are increasing market penetration in lower-income countries by reducing out-of-pocket costs and widening distribution beyond urban private clinics. When governments subsidize products, integrate contraceptives into primary care systems, and include them in national reproductive health campaigns, the contraceptive drugs and devices market gains access to large populations that previously faced affordability and availability barriers. These initiatives also create more predictable institutional purchasing channels, encouraging manufacturers and distributors to strengthen local supply networks and support broader product availability where unmet need has historically constrained demand.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global focus on reproductive health awareness and family planning programs driving adoption | 2.30% | High | Asia Pacific, Africa, North America | High | Near Term |
| Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness | 2.00% | High | North America, Europe | High | Mid Term |
| Expanding government-led contraception access initiatives improving affordability in developing regions | 1.80% | High | Asia Pacific, Latin America, Africa | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the largest regional share of the contraceptive drugs and devices market in 2025, bolstered by broad product availability, established prescribing and retail distribution channels, and consistent use of both short-term and long-acting contraceptive options. The region’s leadership is reinforced by mature healthcare systems, higher awareness of reproductive health management, and routine interaction between patients, physicians, clinics, and pharmacies, which keeps product uptake steady across branded and generic categories.
Asia Pacific is projected to expand at a 6.89% CAGR over the forecast period, with growth in the contraceptive drugs and devices market being propelled by rising awareness of family planning, improving access to healthcare services, and wider availability of modern contraceptive products across urban and semi-urban settings. Adoption is accelerating as healthcare outreach, pharmacy access, and clinical counseling improve practical access to contraceptive choices, while a large population base continues to translate these improvements into stronger regional demand.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Preventive Healthcare IntegrationGermany integrates contraceptive drugs and devices into established reproductive healthcare services with an emphasis on informed clinical guidance. The market supports demand for reliable, evidence-based contraceptive solutions tailored to individual patient needs and long-term reproductive planning.
France 🇫🇷
Public Health AccessibilityFrance supports the contraceptive drugs and devices market through established reproductive health programs and preventive healthcare initiatives. Demand remains focused on accessible contraceptive options, consistent clinical support, and product innovation that enhances patient convenience and adherence.
Italy 🇮🇹
Clinical Care AlignmentItaly emphasizes contraceptive drugs and devices within gynecological care and family planning services. Healthcare providers increasingly recommend personalized contraceptive approaches that balance effectiveness, patient preferences, and long-term reproductive health management.
Japan 🇯🇵
Patient-Centered AdoptionJapan continues expanding awareness and clinical use of modern contraceptive drugs and devices through evolving reproductive healthcare practices. Healthcare professionals focus on improving patient education, treatment suitability, and access to contraceptive options that align with individual preferences.
South Korea 🇰🇷
Expanding Reproductive CareSouth Korea is strengthening access to contraceptive drugs and devices through increasing awareness of reproductive health and preventive care. Market participants prioritize innovative product offerings and patient engagement strategies that support informed contraceptive decision-making across different age groups.
United States 🇺🇸
Comprehensive Product AccessThe U.S. contraceptive drugs and devices market is characterized by broad product availability across prescription and over-the-counter categories. Healthcare providers continue emphasizing patient choice, long-acting contraceptive options, and expanded access through diverse clinical and retail distribution channels.
Segment Leadership and Growth Trends
Contraceptive Drugs and Devices Market Share (%), Product, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportContraceptive Devices held a 66.54% share of the contraceptive drugs and devices market in 2025, reflecting their established position in routine family planning and clinical contraceptive care. Their leadership is maintained through practical use patterns that favor longer-acting and procedure-based options where adherence is less dependent on daily user behavior, which supports continued adoption across healthcare settings. The same operating advantage is also driving growth in the contraceptive drugs and devices market, as users and providers increasingly prefer methods that combine reliability, convenience, and reduced need for frequent intervention compared with short-cycle pharmaceutical alternatives.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Contraceptive Drugs, Contraceptive Devices | Contraceptive Devices | Contraceptive Devices |
Competitive Landscape and Market Positioning
1. Bayer AG (Germany)
2. Organon & Co. (United States)
3. Pfizer Inc. (United States)
4. AbbVie Inc. (United States)
5. Viatris Inc. (United States)
6. Johnson & Johnson (United States)
7. Church & Dwight Co. Inc. (United States)
8. Veru Inc. (United States)
9. Cupid Limited (India)
10. Agile Therapeutics Inc. (United States)
Growing focus on reproductive healthcare and family planning is reshaping the contraceptive drugs and devices market. Market activity is centered around the development of user-friendly products with improved safety profiles and long-term effectiveness. Continuous innovation in delivery systems and formulations, combined with rising awareness regarding women’s healthcare options, is contributing to broader product adoption and stronger market penetration across multiple demographics.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| China Government | Jan-26 | The Chinese government reinstated a 13% value-added tax on contraceptives and condoms, ending a three-decade-old exemption. This fiscal policy shift is a strategic effort to influence demographic trends and address declining national birth rates by increasing the cost and potentially reducing the accessibility of contraceptive products within the domestic market. |
| NEXT Life Sciences | Mar-25 | NEXT Life Sciences initiated clinical trials in Australia for Plan A, a reversible, non-hormonal male contraceptive system designed to occlude the vas deferens. This advancement represents a significant step in diversifying the male contraceptive landscape, addressing a long-standing market gap for long-acting, reversible options that shift reproductive health responsibility beyond traditional methods. |
| Femasys | Mar-25 | Femasys secured CE mark certification for its FemBloc delivery system, the first non-surgical permanent birth control device. This regulatory milestone provides a less invasive alternative to traditional tubal ligation, enabling in-office procedures that reduce surgical risks and recovery times, thereby expanding access to permanent contraception options in the European market. |
| Daré Bioscience | Feb-25 | Daré Bioscience and Theramex entered a co-development agreement for Casea S, a biodegradable, long-acting contraceptive implant. The device is designed to provide contraception for 18–24 months before dissolving, which eliminates the requirement for surgical removal and addresses a critical usability barrier associated with current long-acting reversible contraceptive implants. |
| Perrigo | Mar-24 | Perrigo commenced U.S. retail sales of Opill, the first daily oral contraceptive approved for over-the-counter access. By removing the requirement for a medical prescription, this market entry significantly lowers barriers to hormonal contraception, expanding the commercial reach of progestin-only pills to a broader consumer demographic through major retail and online pharmacy channels. |
| Ministry of Population and Family Development Indonesia | Dec-24 | The Indonesian Ministry of Population and Family Development successfully integrated its contraceptive supply information system with national family planning infrastructure. This digital transformation streamlines data management, improves the accuracy of inventory forecasting, and enhances the efficiency of distribution networks to ensure consistent supply chain reliability for contraceptive products across the country. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Contraceptive Drugs and Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Contraceptive Drugs and Devices Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the contraceptive drugs and devices market?
What is the projected value of the contraceptive drugs and devices industry by 2035?
How is rising reproductive health awareness influencing contraceptive adoption behavior globally?
How are long-acting contraceptive preferences and government initiatives reshaping market access and usage patterns?
Why do Contraceptive Devices dominate the market?
What is driving growth within Contraceptive Devices?
Why is North America the leading region in the contraceptive drugs and devices market?
What is driving contraceptive market growth in Asia Pacific?
Which companies are driving growth in the contraceptive drugs and devices landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization